- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Adherence with urate-lowering therapies for the treatment of gout ; volume:11 ; number:2 ; day:27 ; month:3 ; year:2009 ; pages:1-7 ; date:4.2009
Arthritis Research & Therapy ; 11, Heft 2 (27.3.2009), 1-7, 4.2009
- Urheber
-
Harrold, Leslie R.
- Beteiligte Personen und Organisationen
-
Andrade, Susan E.
Briesacher, Becky A.
Raebel, Marsha A.
Fouayzi, Hassan
Yood, Robert A.
Ockene, Ira S.
SpringerLink (Online service)
- DOI
-
10.1186/ar2659
- URN
-
urn:nbn:de:1111-2016050311922
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Harrold, Leslie R.
- Andrade, Susan E.
- Briesacher, Becky A.
- Raebel, Marsha A.
- Fouayzi, Hassan
- Yood, Robert A.
- Ockene, Ira S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Variation in serum urate levels in the absence of gout and urate lowering therapy
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout
Association between urate-lowering therapies and cognitive decline in community-dwelling older adults
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Variation in serum urate levels in the absence of gout and urate lowering therapy
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout
Association between urate-lowering therapies and cognitive decline in community-dwelling older adults
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Variation in serum urate levels in the absence of gout and urate lowering therapy
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout
Association between urate-lowering therapies and cognitive decline in community-dwelling older adults
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment